Related Experiment Video
Updated: May 24, 2025

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
Published on: September 1, 2023
An audit of people with epilepsy, aged 16-55 years, taking valproate in UK primary care in 2023-4
1General Practitioner and GPwSIe, Fountains Medical Practice, Fountains Health, Delamere Street, Chester, CH1 4DS, United Kingdom.
Purpose:
To audit the standard of clinical care of people with epilepsy (PWE), aged 16-55 years, taking valproate attending UK general practice.
Method:
The case notes of 213 PWE (44 women, 169 men) were audited against standards based on National Institute for Health and Care Excellence (NICE), Drug Safety Unit (DSU) and Medicines and Healthcare products Regulatory Agency (MHRA) guidelines.
Results:
For PWE taking valproate annual review rates in General Practice (GP) were consistently sub-standard, with an average of 42 % for women and 31 % of men in the last 5 years. Fifty percent of men had seen no clinician in 2023 concerning their epilepsy, compared with 23 % women (p = 0.0013). Generalised onset epilepsy was diagnosed in 75 % women and 63 % men. A range of medication was used as add on therapy, with lamotrigine, levetiracetam, and clobazam being most often used. Sixty eight percent of women were actively engaged with the valproate pregnancy prevention program (Valproate PPP); a further 21 % had clear clinical reasons where potential pregnancy was not an issue (history of hysterectomy, severe learning disability) whilst the remaining 11 % of those who should have been engaged with the Valproate PPP were not. Four men had received pre-conceptual counselling. Exposure to valproate for more than 10 years was present in 80 % women and 73 % men. Fifty percent of women and 42 % men were receiving vitamin D supplementation. Eighteen (8 %) people had a bone density scan, 39 % of which were abnormal.
Conclusion:
The standard of care of PWE taking valproate in primary care is concerning, with poor yearly review rates, especially for men. Engagement with the Valproate PPP was absent in 11 % of women, who should have been engaged with this. Long exposure and the lack of vitamin D supplementation needs attention. The re-introduction of the Quality and Outcomes Framework (QOF) for epilepsy with defined clinical targets could potentially address the needs identified.
More Related Videos
10:23Equipment Setup and Artifact Removal for Simultaneous Electroencephalogram and Functional Magnetic Resonance Imaging for Clinical Review in Epilepsy
Published on: June 23, 2023
04:51Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists